Our Science

Founded by the pioneering research of Dr. Xiuling Lu (University of Connecticut) and Dr. Michael Jay (University of North Carolina), we have developed specifically designed nanocarriers, XLNT-1, for targeted delivery of radiotherapies to peritoneal metastatic tumors.

Breakthrough Science

Our groundbreaking innovation, XLNT-1, radionuclide 166Ho-containing nanoparticles, addresses a significant unmet need: treating ovarian cancer metastasis.

Tumor-specific delivery

    • With most IV administered nanotechnologies, only ~ 0.7% of administered dose reaches tumors.

    • XLNT-1 delivered up to 82% dose/g in tumor tissues.

Tumor tissue penetration

    • Conventionally delivered dose can’t reach deep into tumors; incomplete tumor regression.

    • Radiation emitted from XLNT-1 promotes deep tumor penetration of nanoparticles.

Simple and Scalable manufacturing

    • Scaling the manufacturing of radioactive nanoparticles and liposomes is challenging.

    • The manufacture of XLNT-1 is readily scalable; radioactive XLNT-1 is prepared by a simple neutron-activation process that is conducted just prior to administration to the patient.

Improved treatment outcome of difficult-to-treat cancers

    • Current products offer little significant benefit in treating metastasis, resistance & recurrence.

    • Superior survival has been demonstrated with XLNT-1 targeting metastasis and peritoneal carcinoma.

    • XLNT-1 demonstrated a favorable safety profile in preliminary GLP toxicity studies.

    • XLNT-1 enables clinical SPECT or MR imaging for precise dose determination.

Preclinical studies

    • Preclinical studies have demonstrated tumor-specific delivery of radiation, improved survival rates, and favorable safety profile.

    • Our radiotherapeutic nanoparticle product, XLNT-1, is targeting first in-human studies in 2025.